Peter H. O'Donnell to Internationality
This is a "connection" page, showing publications Peter H. O'Donnell has written about Internationality.
Connection Strength
0.036
-
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 11; 18(11):1483-1492.
Score: 0.036